dengue-1 premembrane/envelope DNA vaccine (D1ME100) / U.S. Army Medical Research and Development Command - LARVOL DELTA

Update on efficacy, safety, and immunogenicity of Dengue vaccines: a systematic review and meta-analysis. (PubMed, Infez Med) - "Chimeric Yellow Fever-Dengue Tetravalent Vaccine (CYD-TDV/Dengvaxia®) was assessed in 28 trials, 3 of which reported a pooled vaccine efficacy of 55% (95%CI 47%-62, I 2=86.9%; p <0.001) against Dengue...Takeda-003 (TAK-003/QDENGA®) was evaluated in 23 trials, showing sustained efficacy against virologically confirmed dengue (43.5%-82.1%) and high protection against hospitalization (approximately 87%-90%)...Other promising candidates included other investigational vaccines such as subunit (V180) or DNA-based (TVDV, D1ME100)...Emerging vaccine candidates, including TV003/TV005, Butantan-DV, TDEN, inactivated, subunit, and DNA-based platforms, have also shown promising safety and immunogenicity results in early-phase trials. Future attempts should focus on developing Dengue vaccines that provide safe, balanced, and durable protection against all four Dengue virus serotypes while minimizing the risk of antibody-dependent enhancement, focusing also on special..."

Journal • Retrospective data • Review • Dengue Fever • Infectious Disease